Monitoring levels of DNA in the blood could indicate treatment response

Monitoring levels of DNA shed by tumors and circulating in the bloodstream could help doctors accurately assess how gastroesophageal cancers are responding to treatment, and potentially predict future prognosis, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

READ HERE

SEE ALL NEWS

Recent Posts

Study Suggests a Healthy Diet May Help Keep Low Grade Prostate Cancer From Progressing to More Dangerous States During Active Surveillance Experimental Cancer Drug Eliminates Bone Metastases Caused by Breast Cancer in Lab Models Johns Hopkins Joins Cancer AI Alliance AI ‘Liquid Biopsies’ Using Cell-Free DNA, Protein Biomarkers, Could Aid Early Detection of Ovarian Cancer A Common Culprit Drives Prostate Cancer Progression Immunotherapy Before and After Lung Cancer Surgery Reduces Death Risk, Disease Recurrence Age-Related Changes in Male Fibroblasts Increase Treatment-Resistant Melanoma Scientists Identify Potential New Immune System Target to Head Off the Spread of Breast Cancer Cells Johns Hopkins Researchers Identify Key Markers in Pancreatic Cancer Progression Using a New Analysis Pipeline